BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu Y, Xu X, Ouyang YB, He C, Li NS, Xie C, Peng C, Zhu ZH, Xie Y, Shu X, Lu NH, Zhu Y. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study. Helicobacter 2022;27:e12896. [PMID: 35466521 DOI: 10.1111/hel.12896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu Y, Xu X, Liu X, He C, Ouyang Y, Li N, Xie C, Peng C, Zhu Z, Xie Y, Shu X, Zhu Y, Graham DY, Lu N. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1049908] [Reference Citation Analysis]
2 Hu Y, Zhu Y, Lu NH. The management of Helicobacter pylori infection and prevention and control of gastric cancer in China. Front Cell Infect Microbiol 2022;12:1049279. [PMID: 36530421 DOI: 10.3389/fcimb.2022.1049279] [Reference Citation Analysis]
3 Hu Y, Xu X, Ouyang YB, He C, Li NS, Xie C, Peng C, Zhu ZH, Xie Y, Shu X, Lu NH, Zhu Y. Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication. Helicobacter 2022;27:e12923. [PMID: 36036087 DOI: 10.1111/hel.12923] [Reference Citation Analysis]
4 Hu Y, Lu NH. Letter: a promising Helicobacter pylori regimen - vonoprazan-based therapy. Aliment Pharmacol Ther 2022;56:752-3. [PMID: 35879899 DOI: 10.1111/apt.17114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]